Published in J Antibiot (Tokyo) on March 01, 2004
The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov (2012) 2.51
Genome-minimized Streptomyces host for the heterologous expression of secondary metabolism. Proc Natl Acad Sci U S A (2010) 2.29
Pre-mRNA splicing in disease and therapeutics. Trends Mol Med (2012) 2.23
Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. ACS Chem Biol (2011) 1.77
Spliceostatin A inhibits spliceosome assembly subsequent to prespliceosome formation. Nucleic Acids Res (2010) 1.43
Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells. Mol Cancer Ther (2009) 1.42
Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. Genes Dev (2013) 1.31
Synthetic mRNA splicing modulator compounds with in vivo antitumor activity. J Med Chem (2009) 1.28
Antitumor compounds based on a natural product consensus pharmacophore. J Med Chem (2008) 1.17
The spliceosome as target for anticancer treatment. Br J Cancer (2008) 1.15
The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. Drug Discov Today (2012) 1.10
ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system. Acta Pharmacol Sin (2010) 1.08
Genomics-guided discovery of thailanstatins A, B, and C As pre-mRNA splicing inhibitors and antiproliferative agents from Burkholderia thailandensis MSMB43. J Nat Prod (2013) 1.00
Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs. J Biol Chem (2013) 0.97
Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell (2016) 0.96
A thermally targeted peptide inhibitor of symmetrical dimethylation inhibits cancer-cell proliferation. Peptides (2010) 0.96
Enantioselective total synthesis of pladienolide B: a potent spliceosome inhibitor. Org Lett (2012) 0.95
Pre-mRNA splicing-modulatory pharmacophores: the total synthesis of herboxidiene, a pladienolide-herboxidiene hybrid analog and related derivatives. ACS Chem Biol (2013) 0.93
A synthetic entry to pladienolide B and FD-895. Bioorg Med Chem Lett (2007) 0.92
Design, synthesis and initial biological evaluation of a novel pladienolide analog scaffold. Medchemcomm (2011) 0.91
Optimization of antitumor modulators of pre-mRNA splicing. J Med Chem (2013) 0.91
A high-throughput splicing assay identifies new classes of inhibitors of human and yeast spliceosomes. J Biomol Screen (2013) 0.90
The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. Oncotarget (2015) 0.88
Identification of small molecule inhibitors of pre-mRNA splicing. J Biol Chem (2014) 0.87
A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest New Drugs (2013) 0.87
Structure of FD-895 revealed through total synthesis. Org Lett (2012) 0.86
Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer. J Nucleic Acids (2011) 0.86
Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages. RNA (2016) 0.85
Therapeutic targeting of splicing in cancer. Nat Med (2016) 0.85
Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. Elife (2017) 0.84
Stabilized cyclopropane analogs of the splicing inhibitor FD-895. J Med Chem (2013) 0.84
High antitumor activity of pladienolide B and its derivative in gastric cancer. Cancer Sci (2013) 0.82
Effects of thailanstatins on glucocorticoid response in trabecular meshwork and steroid-induced glaucoma. Invest Ophthalmol Vis Sci (2013) 0.80
Small Molecule Modulators of Pre-mRNA Splicing in Cancer Therapy. Trends Mol Med (2015) 0.79
Spliceostatin hemiketal biosynthesis in Burkholderia spp. is catalyzed by an iron/α-ketoglutarate-dependent dioxygenase. Proc Natl Acad Sci U S A (2014) 0.79
Modulating splicing with small molecular inhibitors of the spliceosome. Wiley Interdiscip Rev RNA (2016) 0.77
Global analysis of pre-mRNA subcellular localization following splicing inhibition by spliceostatin A. RNA (2016) 0.75
A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. Bioorg Med Chem Lett (2016) 0.75
Radiosynthesis of antitumor spliceosome modulators. Appl Radiat Isot (2011) 0.75
Microbial and Natural Metabolites That Inhibit Splicing: A Powerful Alternative for Cancer Treatment. Biomed Res Int (2016) 0.75
Ruthenium-Catalyzed Olefin Metathesis after Tetra-n-butylammonium Fluoride-Mediated Desilylation. Tetrahedron Lett (2012) 0.75
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol (2002) 5.52
Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol (2007) 3.97
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol (2002) 3.08
Effect on tumor cells of blocking survival response to glucose deprivation. J Natl Cancer Inst (2004) 2.30
Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem (2004) 2.17
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res (2008) 2.05
Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res (2003) 2.04
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer (2008) 2.04
Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst (2006) 2.00
An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res (2002) 1.82
Functional implications of the IL-6 signaling pathway in keloid pathogenesis. J Invest Dermatol (2006) 1.82
Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res (2005) 1.65
Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells. J Biol Chem (2004) 1.61
Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem (2006) 1.55
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res (2013) 1.52
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci (2008) 1.43
Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1). Oncogene (2004) 1.42
Verification of the Robin and Graham classification system of hip disease in cerebral palsy using three-dimensional computed tomography. Dev Med Child Neurol (2011) 1.42
Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res (2012) 1.42
Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr Med Chem (2009) 1.38
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther (2014) 1.37
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. Eur J Cancer (2010) 1.30
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Sci (2007) 1.30
Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res (2011) 1.28
Biological validation that SF3b is a target of the antitumor macrolide pladienolide. FEBS J (2011) 1.26
The Th2 cytokine, interleukin-4, abrogates the cohesion of normal stratum corneum in mice: implications for pathogenesis of atopic dermatitis. Exp Dermatol (2012) 1.26
Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci Transl Med (2011) 1.26
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target. J Natl Cancer Inst (2005) 1.23
Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett (2013) 1.22
Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. Cancer Res (2010) 1.21
Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb. Clin Cancer Res (2012) 1.17
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther (2012) 1.17
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci (2014) 1.13
Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem Biophys Res Commun (2003) 1.13
Synthesis and biological relationships of 3',6-substituted 2-phenyl-4-quinolone-3-carboxylic acid derivatives as antimitotic agents. Bioorg Med Chem (2005) 1.13
Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res (2012) 1.12
Gender differences in 3D morphology and bony impingement of human hips. J Orthop Res (2010) 1.11
SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric cancer cells. J Biol Chem (2008) 1.10
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Mol Cancer Ther (2005) 1.10
Csk defines the ability of integrin-mediated cell adhesion and migration in human colon cancer cells: implication for a potential role in cancer metastasis. Oncogene (2004) 1.09
Ultrasound screening of periarticular soft tissue abnormality around metal-on-metal bearings. J Arthroplasty (2011) 1.09
ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system. Acta Pharmacol Sin (2010) 1.08
Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci (2010) 1.06
Leptosins isolated from marine fungus Leptoshaeria species inhibit DNA topoisomerases I and/or II and induce apoptosis by inactivation of Akt/protein kinase B. Cancer Sci (2005) 1.06
Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Res (2002) 1.05
Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. Biol Pharm Bull (2007) 1.05
Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly. Mol Microbiol (2003) 1.05
Progression and cessation of collapse in osteonecrosis of the femoral head. Clin Orthop Relat Res (2002) 1.05
Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. Antimicrob Agents Chemother (2011) 1.04
Eleven- to 14-year follow-up results of cementless total hip arthroplasty using a third-generation alumina ceramic-on-ceramic bearing. J Arthroplasty (2011) 1.03
E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci (2009) 1.02
Distribution of TRAP-positive cells and expression of HIF-1alpha, VEGF, and FGF-2 in the reparative reaction in patients with osteonecrosis of the femoral head. J Orthop Res (2009) 1.02
Significance of lesion size and location in the prediction of collapse of osteonecrosis of the femoral head: a new three-dimensional quantification using magnetic resonance imaging. J Orthop Res (2002) 1.02
Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor. Eur J Cancer (2009) 1.01
Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest. Biochem Biophys Res Commun (2008) 1.01
Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase. Biol Pharm Bull (2009) 1.01
Synthesis and biological evaluation of boronic acid containing cis-stilbenes as apoptotic tubulin polymerization inhibitors. ChemMedChem (2006) 1.00
Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. Cancer Res (2003) 0.99
Nucleotide sequence variation is frequent in the mitochondrial DNA displacement loop region of individual human tumor cells. Mol Cancer Res (2005) 0.99
Construction of a gamete-enriched gene pool and RNAi-mediated functional analysis in Dictyostelium discoideum. Mech Dev (2003) 0.99
In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother (2011) 0.99
E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin Cancer Res (2009) 0.98
Stereochemistry of pladienolide B. J Antibiot (Tokyo) (2007) 0.98
Suzuki-Miyaura coupling reaction using pentafluorophenylboronic acid. Org Lett (2005) 0.98
An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker. Clin Cancer Res (2004) 0.97
Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signalling. Biochem J (2004) 0.97
Antiproliferative and antiangiogenic activities of smenospongine, a marine sponge sesquiterpene aminoquinone. Mar Drugs (2011) 0.96
Antibacterial and antiproliferative activity of cationic fullerene derivatives. Bioorg Med Chem Lett (2003) 0.95
Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226. Biochem Pharmacol (2007) 0.94
Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumor agent. J Med Chem (2010) 0.93
Validity and responsiveness of the Oxford hip score in a prospective study with Japanese total hip arthroplasty patients. J Orthop Sci (2009) 0.92
The G protein-coupled receptor T-cell death-associated gene 8 (TDAG8) facilitates tumor development by serving as an extracellular pH sensor. Proc Natl Acad Sci U S A (2010) 0.92
Rapid quantification of periodontitis-related bacteria using a novel modification of Invader PLUS technologies. Microbiol Res (2008) 0.92
Potential pathophysiological role of D-amino acid oxidase in schizophrenia: immunohistochemical and in situ hybridization study of the expression in human and rat brain. J Neural Transm (Vienna) (2009) 0.91
Synthesis and pharmacological evaluation of the novel pseudo-symmetrical tamoxifen derivatives as anti-tumor agents. Biochem Pharmacol (2007) 0.91
Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression. Int J Cancer (2002) 0.91
Minimum five-year follow-up wear measurement of longevity highly cross-linked polyethylene cup against cobalt-chromium or zirconia heads. J Arthroplasty (2009) 0.91
Synthesis of functional proteins by mixing peptide motifs. Chem Biol (2004) 0.91
AMF-26, a novel inhibitor of the Golgi system, targeting ADP-ribosylation factor 1 (Arf1) with potential for cancer therapy. J Biol Chem (2011) 0.91
Proteomics-based identification of biomarkers for predicting sensitivity to a PI3-kinase inhibitor in cancer. Biochem Biophys Res Commun (2006) 0.90
Does CT-based navigation improve the long-term survival in ceramic-on-ceramic THA? Clin Orthop Relat Res (2012) 0.90
Synovial joint fluid cytokine levels in hip disease. Rheumatology (Oxford) (2013) 0.90
Highly enantioselective and efficient synthesis of flavanones including pinostrobin through the rhodium-catalyzed asymmetric 1,4-addition. Org Lett (2011) 0.90
Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am J Pathol (2012) 0.90
Triterpene saponins from the roots of Clematis chinensis. J Nat Prod (2004) 0.90
The results of a press-fit-only technique for acetabular fixation in hip dysplasia. J Arthroplasty (2010) 0.90
Jogging after total hip arthroplasty. Am J Sports Med (2013) 0.89
Total synthesis of the bicyclic depsipeptide HDAC inhibitors spiruchostatins A and B, 5''-epi-spiruchostatin B, FK228 (FR901228) and preliminary evaluation of their biological activity. Chemistry (2009) 0.89
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. Bioorg Med Chem (2012) 0.89
Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. Lung Cancer (2010) 0.89
Effect of ionizing irradiation on human esophageal cancer cell lines by cDNA microarray gene expression analysis. J Nippon Med Sch (2004) 0.88
Urukthapelstatin A, a novel cytotoxic substance from marine-derived Mechercharimyces asporophorigenens YM11-542. I. Fermentation, isolation and biological activities. J Antibiot (Tokyo) (2007) 0.88
Highly enantioselective and efficient synthesis of methyl (R)-o-chloromandelate with recombinant E. coli: toward practical and green access to clopidogrel. Org Biomol Chem (2007) 0.87